-
Mashup Score: 1Medication guide for dose adjustment and management of cardiotoxicity and lipid metabolic adverse events of oral antineoplastic therapy - 7 month(s) ago
ObjectiveThe management of cardiotoxicity concerning the use of oral antineoplastic agents (OAAs) is a challenge for healthcare professionals. Our objective was to create a comprehensive medication management guide with dose adjustment recommendations on OAAs concerning cardiotoxic and lipid metabolic adverse events (AEs) to assist healthcare professionals when prescribing OAAs.Materials and methodsA review of the available information on all dose adjustments necessary to safely prescribe and dispense OAAs concerning cardiotoxicity was conducted. In January 2023, we identified all OAAs authorized by the European Medicines Agency (EMA). For each drug, the latest summary of product characteristics (SPC) approved by the EMA and the tertiary data source Lexicomp® were reviewed. Cardiotoxic AEs were recorded, namely, QT interval prolongation, decrease in left ventricular ejection fraction (LVEF), imbalances in blood pressure (hypertension and hypotension), alterations in heart rate (tachyca
Source: www.frontiersin.orgCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1Permissive Cardiotoxicity: The Clinical Crucible of Cardio-Oncology - 7 month(s) ago
Abstract The field of cardio-oncology was born from the necessity for recognition and management of cardiovascular diseases among patients with cancer. This need for this specialty continues to gro…
Source: www.jacc.orgCategories: Latest Headlines, Partners & KOLsTweet
-
Mashup Score: 1
Background: Our goal was to evaluate the ability of cardiovascular magnetic resonance for detecting and predicting cardiac dysfunction in patients receiving cancer therapy. Left ventricular ejection
Source: www.ahajournals.orgCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 9Priorities in Cardio-Oncology Basic and Translational Science: GCOS 2023 Symposium Proceedings: JACC: CardioOncology State-of-the-Art Review - 7 month(s) ago
Abstract Despite improvements in cancer survival, cancer therapy–related cardiovascular toxicity has risen to become a prominent clinical challenge. This has led to the growth of the burgeoning fie…
Source: www.jacc.orgCategories: Latest Headlines, Partners & KOLsTweet
-
Mashup Score: 0High BMI raises risk in of cardiotoxicity for breast cancer patients undergoing chemotherapy - 9 month(s) ago
Higher body mass index associated with cardiotoxicity in breast cancer patients, new study based in Columbia reveals.
Source: www.oncology-central.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 3RBL2 Regulates Cardiac Sensitivity to Anthracycline Chemotherapy: - 9 month(s) ago
Abstract Background Anthracycline chemotherapies cause heart failure in a subset of cancer patients. We previously reported that the anthracycline doxorubicin (DOX) induces cardiotoxicity through t…
Source: www.jacc.orgCategories: Latest Headlines, Partners & KOLsTweet-
In this mechanistic #JACCCardioOnc study, the loss of Rbl2 increases sensitivity to DOX-induced cardiotoxicity suggesting RBL2 could be used as a biomarker to predict the risk of #cardiotoxicity before the initiation of #anthracycline-based chemotherapy. https://t.co/F4pih4YfwS https://t.co/xlfg9wxTTF
-
-
Mashup Score: 0
In season 3, episode 9 of Targeted Talks, Mohammed Salhab, MD, and Chris Fine, MD, FACC, have a special discussion about cardiotoxicity from immune checkpoint inhibitor therapy in patients with cancer.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1Racial disparities in cardiotoxicity after chemotherapy - 1 year(s) ago
“The most important message is to look at preexisting cardiovascular disease, oncology diagnosis, and be aware of existing disparities in a specific cancer and CVD.”
Source: www.mdedge.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Black Patients With Cancer May Be More Likely to Experience Cardiotoxicity Following Chemotherapy - The ASCO Post - 1 year(s) ago
By The ASCO Post Staff Posted: 4/24/2023 1:32:00 PM Last Updated: 4/24/2023 3:14:25 PM Chemotherapy may be associated with a 71% increased risk of treatment-related cardiotoxicity—including heart failure and cerebrovascular disease—among Black patients or patients of African ancestry compared with White…
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 5CAR T-cell cancer therapies: do not forget the heart - 1 year(s) ago
This editorial refers to ‘Biomarkers and cardiovascular outcomes in chimeric antigen receptor T-cell therapy recipients’, by S.S. Mahmood et al., https://doi.or
Source: OUP AcademicCategories: Cardiology News and Journals, Latest HeadlinesTweet
Medication guide for dose adjustment and management of #cardiotoxicity and lipid metabolic adverse events of oral antineoplastic therapy #CardioOnc #hematology #oncology #cardiology #pharmacy https://t.co/aGylkZDpUD